<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169988</url>
  </required_header>
  <id_info>
    <org_study_id>05-04-103</org_study_id>
    <nct_id>NCT00169988</nct_id>
  </id_info>
  <brief_title>Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms</brief_title>
  <official_title>Sertraline Alone vs. in Combination With Risperidone in the Treatment of Attenuated Positive and Negative Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica N.V., Belgium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Recognition and Prevention (RAP) Program is conducting a research study comparing an&#xD;
      antidepressant, sertraline, alone versus in combination with a second-generation&#xD;
      antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts,&#xD;
      suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention&#xD;
      and social skills in adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients are enrolled in a 16-week trial consisting of symptom and side effects&#xD;
      ratings (10 visits), monthly blood and urine tests, and neuropsychological testing at the&#xD;
      first and last visits. At the initial appointment, all patients are assigned to sertraline&#xD;
      and are randomly assigned to an adjunctive risperidone or placebo group. The treating&#xD;
      physician is also blind to the medication assignment, which allows both the doctor and the&#xD;
      patient to assess side effects and symptom improvement, unbiased by expectation. All patients&#xD;
      receive an active medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on attenuated positive symptom scale at 16 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Score on attenuated negative symptom scale at 16 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on social functioning measure at 16 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on academic functioning measure at 16 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on cognitive measures at 16 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Prodromal Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline-primary</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants are between the ages of 12 and 22.&#xD;
&#xD;
          -  Participants are English-speaking.&#xD;
&#xD;
          -  Participants are experiencing one or more symptoms like unusual thoughts,&#xD;
             suspiciousness, or unusual perceptual experiences.&#xD;
&#xD;
          -  Participants meet additional RAP criteria (evaluated during screening and interview).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants have been diagnosed with an Axis I psychotic disorder, including:&#xD;
             schizophreniform disorder, schizophrenia, schizoaffective disorder, bipolar disorder,&#xD;
             or major depression with psychotic features.&#xD;
&#xD;
          -  Participants have a history of neurological, neuroendocrine, or other medical&#xD;
             conditions known to affect the brain.&#xD;
&#xD;
          -  Participants have a medical condition that contraindicates treatment with sertraline&#xD;
             or risperidone.&#xD;
&#xD;
          -  Participants have past or current substance dependence.&#xD;
&#xD;
          -  Participants are currently taking and responding well to antidepressant or&#xD;
             antipsychotic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara A Cornblatt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Long Island Jewish Medical Center (LIJMC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph U Correll, MD</last_name>
    <role>Study Director</role>
    <affiliation>LIJMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RAP Program, Dept. of Psychiatry Research, The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rapprogram.org/</url>
    <description>RAP Program Homepage</description>
  </link>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>December 16, 2009</last_update_submitted>
  <last_update_submitted_qc>December 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2009</last_update_posted>
  <keyword>clinical high risk</keyword>
  <keyword>attenuated positive symptoms</keyword>
  <keyword>attenuated negative symptoms</keyword>
  <keyword>cognition</keyword>
  <keyword>functional status</keyword>
  <keyword>prodromal psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

